Brought to you by 
Pfizer pays $15.4bn in cash, $1.75bn in debt for Hospira
16 Nov 2021
Executive Summary
Pfizer Inc. bought generics firm Hospira Inc. for $15.4bn in cash--$90 per share (a 39% premium)--plus $1.75bn in debt, and will finance the deal through a combination of cash (two-thirds) and debt (one-third).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer pays $15.4bn in cash, $1.75bn in debt for Hospira
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice